Abattis Bioceuticals Profit Margin

The latest profit margin for ATTBF is -852.4% as of September 2019. That compares with -931940.11% in the prior-year period — up 99.9% year over year. That is below the Healthcare sector average of 13.71%. Investors often review this figure alongside Abattis Bioceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, ATTBF's profit margin moved from -931940.11% to -852.4% — a 99.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Abattis Bioceuticals's valuation or profitability profile.

Against Healthcare companies, ATTBF currently prints -852.4% for profit margin, while the sector average sits near 13.71%. That is roughly 6317.0% below the sector mean. Large gaps often invite a closer look at Abattis Bioceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Abattis Bioceuticals converts resources into returns. At -852.4%, ATTBF may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -931940.11% in the prior-year period — up 99.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ATTBF's profit margin (-852.4%), review year-over-year change from -931940.11%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.